A Keilmann1, D Hajioff2, U Ramaswami3. 1. Department for ENT and Communication Disorders, University Hospital, Langenbeckstr. 1, 55101, Mainz, Germany. keilmann@kommunikation.klinik.uni-mainz.de. 2. Department of Otolaryngology, Southmead Hospital, Bristol, UK. 3. Department of Paediatric Endocrinology, Diabetes and Metabolism, Addenbrooke's University Teaching Hospital, Cambridge, UK.
Abstract
BACKGROUND: Hearing loss and tinnitus are common symptoms in Fabry disease and increase in prevalence with age. This study aimed to provide an epidemiological description of hearing impairment and tinnitus in children with Fabry disease in the Fabry Outcome Survey (FOS), an international database to assess the natural history of Fabry disease and the efficacy of enzyme replacement therapy with agalsidase alpha. METHODS: Signs and symptoms questionnaires were completed for 543 children with Fabry disease. Pure-tone audiograms were obtained from 101 children (53 girls, 48 boys). RESULTS: On questioning, 33% of the children (n = 179) reported subjective hearing impairment. However, when assessed by age-appropriate audiometry, only 19 of 101 patients (19%) had a persistent hearing loss at least one frequency. Of these, 14 had a high-frequency hearing loss, 4 a pan-frequency hearing loss, and 1 a pattern typical of noise-induced loss. Of the 101 children with audiometry, 44 complained of tinnitus. Only 2 children reported sudden hearing loss, which was not verified by audiometry. Children with tinnitus had greater disease severity scores. CONCLUSIONS: Hearing loss is a well-known clinical manifestation in patients with Fabry disease. It was reported in significant numbers of children in the FOS signs and symptoms questionnaire, but confirmed in only 19% by formal audiometry. The subjective hearing impairment may have been due to middle-ear effusions in many cases. Tinnitus is a well-recognized symptom in Fabry disease and can present in childhood. The presence of tinnitus correlated with overall disease severity.
BACKGROUND:Hearing loss and tinnitus are common symptoms in Fabry disease and increase in prevalence with age. This study aimed to provide an epidemiological description of hearing impairment and tinnitus in children with Fabry disease in the Fabry Outcome Survey (FOS), an international database to assess the natural history of Fabry disease and the efficacy of enzyme replacement therapy with agalsidase alpha. METHODS: Signs and symptoms questionnaires were completed for 543 children with Fabry disease. Pure-tone audiograms were obtained from 101 children (53 girls, 48 boys). RESULTS: On questioning, 33% of the children (n = 179) reported subjective hearing impairment. However, when assessed by age-appropriate audiometry, only 19 of 101 patients (19%) had a persistent hearing loss at least one frequency. Of these, 14 had a high-frequency hearing loss, 4 a pan-frequency hearing loss, and 1 a pattern typical of noise-induced loss. Of the 101 children with audiometry, 44 complained of tinnitus. Only 2 children reported sudden hearing loss, which was not verified by audiometry. Children with tinnitus had greater disease severity scores. CONCLUSIONS:Hearing loss is a well-known clinical manifestation in patients with Fabry disease. It was reported in significant numbers of children in the FOS signs and symptoms questionnaire, but confirmed in only 19% by formal audiometry. The subjective hearing impairment may have been due to middle-ear effusions in many cases. Tinnitus is a well-recognized symptom in Fabry disease and can present in childhood. The presence of tinnitus correlated with overall disease severity.
Authors: E Seifert; S Brosch; A G Dinnesen; A Keilmann; C Neuschaefer-Rube; O Goldschmidt; A Nickisch; W Reuter; M Röhrs; M Tigges Journal: HNO Date: 2005-04 Impact factor: 1.284
Authors: D Hajioff; S Hegemann; S Hegemannn; G Conti; M Beck; G Sunder-Plassmann; U Widmer; A Mehta; A Keilmann Journal: Eur J Clin Invest Date: 2006-09 Impact factor: 4.686
Authors: S Hegemann; D Hajioff; G Conti; M Beck; G Sunder-Plassmann; U Widmer; A Mehta; A Keilmann Journal: Eur J Clin Invest Date: 2006-09 Impact factor: 4.686
Authors: M Ries; H J Kim; C K Zalewski; M A Mastroianni; D F Moore; R O Brady; J M Dambrosia; R Schiffmann; C C Brewer Journal: Brain Date: 2006-11-14 Impact factor: 13.501
Authors: Markus Ries; Uma Ramaswami; Rossella Parini; Bengt Lindblad; Catharina Whybra; Ingrid Willers; Andreas Gal; Michael Beck Journal: Eur J Pediatr Date: 2003-09-20 Impact factor: 3.183
Authors: Dawn A Laney; Dawn S Peck; Andrea M Atherton; Linda P Manwaring; Katherine M Christensen; Suma P Shankar; Dorothy K Grange; William R Wilcox; Robert J Hopkin Journal: Genet Med Date: 2014-09-18 Impact factor: 8.822
Authors: Nadine A M E van der Beek; Hans Verschuure; Arnold J J Reuser; Ans T van der Ploeg; Pieter A van Doorn; René M L Poublon Journal: J Inherit Metab Dis Date: 2011-10-15 Impact factor: 4.982
Authors: Maria Köping; Wafaa Shehata-Dieler; Dieter Schneider; Mario Cebulla; Daniel Oder; Jonas Müntze; Peter Nordbeck; Christoph Wanner; Rudolf Hagen; Sebastian P Schraven Journal: Orphanet J Rare Dis Date: 2018-08-15 Impact factor: 4.123
Authors: E Suntjens; W A Dreschler; J Hess-Erga; R Skrunes; F A Wijburg; G E Linthorst; C Tøndel; M Biegstraaten Journal: J Inherit Metab Dis Date: 2017-05-31 Impact factor: 4.982